S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 27, 2026

What Changed

Apnimed filed an amended S-1 registration statement on July 27, 2026. The biotech company developing treatments for sleep apnea and narcolepsy is moving closer to pricing its IPO. The filing does not yet disclose share price range or total raise size, but the amendment signals institutional roadshow activity has begun.

The Numbers That Matter

| IPO Component | Typical Range | Impact on $1M Allocation | |--------------|---------------|--------------------------|| | Post-IPO lockup period | 90 to 180 days | No liquidity access until Q1 2027 earliest | | First-day volatility (biotech avg) | 18% to 34% swing | $180K to $340K mark-to-market move | | Institutional allocation priority | 70% to 85% of total offering | Retail access limited to 15% to 30% of shares | | Typical fee load (underwriter spread) | 5.5% to 7.0% embedded in pricing | $55K to $70K in costs on $1M position |

What This Means for Your Portfolio

A $500K allocation to Apnimed at IPO pricing carries $27,500 to $35,000 in embedded underwriting fees before you own a single share. Your cost basis starts 5.5% to 7.0% above the institutional entry point. On a $1M position, first-day volatility in line with recent biotech IPOs (Neumora Therapeutics moved 28% on debut in May 2024) translates to $280,000 in paper gains or losses before the first earnings call.

Scenario Analysis

| Portfolio Allocation | First-Day Gain (20% pop) | First-Day Loss (15% drop) | Net After Tax (Federal + CA, 37% short-term rate) | |---------------------|--------------------------|---------------------------|--------------------------------------------------|| | $500K | $100,000 | -$75,000 | $63,000 gain / -$75,000 loss | | $1M | $200,000 | -$150,000 | $126,000 gain / -$150,000 loss | | $2M | $400,000 | -$300,000 | $252,000 gain / -$300,000 loss |

Tax treatment assumes short-term capital gains on any sale within 12 months of IPO pricing. No qualified dividend treatment applies to biotech equities with no earnings history. California residents add 13.3% state tax on gains, reducing net proceeds to 49.7 cents per dollar of gross gain.

IPO Access Tiers and Allocation Reality

Your effective access depends on custodial relationship and total assets under management with the lead underwriter. Morgan Stanley, Goldman Sachs, and JPMorgan typically lead biotech IPOs. If you hold under $3M with the lead bank, your allocation will be capped at $50K to $100K regardless of demand. Fidelity and Schwab retail IPO programs allocate via lottery with no size guarantee.

Biotech IPO Performance: 12-Month Trailing Data

Apnimed's clinical pipeline includes APM-101 for obstructive sleep apnea (Phase 2) and APM-201 for narcolepsy (Phase 1). Both indications require multi-year FDA approval timelines. No revenue is expected before 2028. Your position carries binary risk: trial success drives 100%+ upside, trial failure drives 60% to 80% drawdowns within 48 hours of disclosure.

Frequently Asked Questions

Q: What factors should high-net-worth investors consider when evaluating direct IPO exposure to a single biotech issuer?
A: Consider your total liquid net worth, concentration limits relative to your overall portfolio, volatility tolerance, and time horizon. Many investors with $2M or more in liquid net worth limit single-position exposure to 5% or less to manage concentration risk, though this depends on individual circumstances.

Q: How does lockup expiration affect share price after the IPO?
A: Insider selling begins 90 to 180 days post-IPO, typically adding 15% to 25% more shares to float and driving 10% to 18% price declines in the two weeks following expiration.

Q: Can I short Apnimed shares on day one to hedge a long position?
A: No. Borrow availability for newly public biotech equities is typically zero for 30 to 60 days post-IPO, and when available, carries borrow costs of 8% to 15% annualized.

Q: What is the tax treatment if I flip IPO shares within the first week?
A: Ordinary income rates apply to any gain, with no holding period benefit. For high earners in California, federal short-term capital gains tax of 37% plus California state tax of 13.3% create combined tax pressure, though actual effective rates vary by individual circumstances and filing status.

Run the Numbers

Use CalcMoney's Calculate Your After-Tax RSU Proceeds to model your exact net position after embedded fees, first-day volatility, and short-term capital gains treatment at your specific state and federal tax rates.

Disclaimer

This article is provided for informational purposes only and should not be construed as professional financial advice. Consult with a qualified financial advisor or tax professional before making any investment decisions, particularly regarding IPO allocations or biotech equity exposure.

Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.

---

You Might Also Like

• S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 21, 2026
• S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 22, 2026
• S-1 Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 23, 2026
• S-1MEF Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 24, 2026

Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.